Through flow cytometric analysis of control (Vector) or Runx3 KD AML cells, we found a slight increase in the percentage of G2/S/M-phase cells and G0-phase cells, accompanied by a minor decrease in the percentage of G1-phase cells after Runx3 knockdown (1.14-fold and 1.34-fold increase in G2/S/M-phase cells and G0-phase cells, 12.8% reduction in G1-phase cells, respectively; Figure 3A and Supplementary Figure S3). The gene discussed is RUNX3; the disease is acute myeloid leukemia.